Impact of immunosuppression and acute rejection on hepatitis B recurrence.
Platz
K P
KP
Department of Surgery, Virchow Clinic, Humboldt University Berlin, Germany.
Mueller
A R
AR
Haller
G W
GW
Berg
T
T
Neuhaus
R
R
Bechstein
W O
WO
Hopf
U
U
Lobeck
H
H
Neuhaus
P
P
D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology*; D006085:Graft Survival; D006509:Hepatitis B / Q000276:immunology* / Q000601:surgery* / Q000628:therapy; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D016559:Tacrolimus / Q000627:therapeutic use
D007136:Immunoglobulins; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus; C045213:hepatitis B hyperimmune globulin